AI Article Synopsis
- Sicca syndrome, characterized by dry mouth, can occasionally occur as an immune-related side effect of cancer treatments like immune checkpoint inhibitors.
- A case study of a 70-year-old man treated for metastatic renal cell carcinoma revealed that he developed sicca syndrome after receiving ipilimumab and nivolumab.
- The patient's symptoms improved after 36 weeks of treatment with pilocarpine hydrochloride, demonstrating that sicca syndrome can be managed without stopping immunotherapy.
Article Abstract
Introduction: Dry mouth is the main symptom of sicca syndrome, which rarely occurs as an immune-related adverse event. Here we report a case of sicca syndrome caused by immune checkpoint inhibitor treatment.
Case Presentation: A 70-year-old man was diagnosed with left renal cell carcinoma after radical left nephrectomy. Nine years later, computed tomography revealed a metastatic nodule in the upper left lung lobe. Subsequently, ipilimumab and nivolumab were administered for recurrent disease. After 13 weeks of treatment, xerostomia and dysgeusia were noted. Salivary gland biopsy revealed lymphocyte and plasma cell infiltration in the salivary glands. Sicca syndrome was diagnosed and pilocarpine hydrochloride was prescribed without corticosteroids, with continuation of immune checkpoint inhibitor therapy. The symptoms alleviated after 36 weeks of treatment, with shrinkage of the metastatic lesions.
Conclusion: We experienced sicca syndrome caused by immune checkpoint inhibitors. Sicca syndrome improved without steroids and the immunotherapy could be continued.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978085 | PMC |
| http://dx.doi.org/10.1002/iju5.12573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!